Filing Flows › Comparisons › MXCT vs FOXO
Maxcyte vs Foxo Technologies: MXCT and FOXO compared
Maxcyte is the larger company: $7.3M of revenue in its latest quarter (Q2 2026) against $4.7M for Foxo Technologies (Q2 2026). Foxo Technologies is growing faster (-10% against -14% a year earlier). Foxo Technologies is more profitable, with an operating margin of 185.5% against -140.7%.
Where the money goes: MXCT and FOXO
Maxcyte (MXCT) · Q2 2026
Maxcyte, Q2 2026: revenue $7.3M (-14% year over year), operating margin -140.7%, net loss $8.9M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
Foxo Technologies (FOXO) · Q2 2026
Foxo Technologies, Q2 2026: revenue $4.7M (-10% year over year), operating margin 185.5%, net earnings $8.1M, operating cash flow $299K. The chart follows the revenue to costs, profit and cash.
| Maxcyte (MXCT) | Foxo Technologies (FOXO) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $7.3M | $4.7M |
| Revenue growth, Y/Y | -14% | -10% |
| Operating margin | -140.7% | 185.5% |
| Net earnings | −$8.9M | $8.1M |
| Net margin | -122.0% | 172.6% |
| Operating cash flow | −$4.7M | $299K |
| Free cash flow | — | $293K |
Where the revenue comes from
Maxcyte
- Product sales: $4.1M (56%)
- Licenses: $2.6M (36%)
- Assay and other service revenue: $583K (8%)
Foxo Technologies
- Health Cares: $4.5M (95%)
- Life Science Services: $238K (5%)
- Labs: $6K (0%)
Questions
Which is bigger, Maxcyte or Foxo Technologies?
Maxcyte is the larger company: $7.3M of revenue in its latest quarter (Q2 2026) against $4.7M for Foxo Technologies (Q2 2026).
Is Maxcyte or Foxo Technologies growing faster?
Foxo Technologies is growing faster (-10% against -14% a year earlier).
Which is more profitable, Maxcyte or Foxo Technologies?
Foxo Technologies is more profitable, with an operating margin of 185.5% against -140.7%.
More: Maxcyte earnings · how Maxcyte makes money · Foxo Technologies earnings · how Foxo Technologies makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.